Skip to main content
Top
Published in: Journal of Hematopathology 4/2020

01-12-2020 | Lymphoma | Original Article

Expression of CD180 in common B cell neoplasms using immunohistochemistry

Authors: Ahmad T. Mansour, Tamadur A. Mahasneh, Sahar Mustafa, Sarah Shawash, Omar Jaber, Tariq N. Adily

Published in: Journal of Hematopathology | Issue 4/2020

Login to get access

Abstract

Diagnosis of low-grade B cell lymphoma can be challenging especially on limited cytological and histological samples, CD180 is Toll-like receptor that was found to be of value in the diagnosis of marginal zone lymphoma using flow cytometry. In this pilot study, we examine the expression of CD180, using an immunohistochemical method, on a number of common B cell lymphoproliferative neoplasms. Immunohistochemical staining for sixty-seven cases of five B cell neoplasms, specifically, marginal zone lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma was performed on archived, paraffin-embedded, formalin-fixed tissue. CD180 expression is preserved in all cases of marginal zone lymphoma, sixteen out of 17 cases of follicular lymphoma cases, and none of the diffuse large B cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma cases. One in 12 cases of mantle cell lymphoma shows weak and focal staining. Using CD180 immunohistochemical stain can be valuable and offer some help in the diagnosis of B cell neoplasms, especially on small tissue samples.
Literature
1.
go back to reference Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL (2005) Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol 6(6):571–578CrossRef Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL (2005) Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol 6(6):571–578CrossRef
2.
go back to reference Egli N, Zajonz A, Burger MT, Schweighoffer T (2015) Human CD180 transmits signals via the PIM-1L kinase. PLoS One 10(11):e0142741CrossRef Egli N, Zajonz A, Burger MT, Schweighoffer T (2015) Human CD180 transmits signals via the PIM-1L kinase. PLoS One 10(11):e0142741CrossRef
3.
go back to reference Chaplin JW, Kasahara S, Clark EA, Ledbetter JA (2011) Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent pathway. J Immunol 187(8):4199–4209CrossRef Chaplin JW, Kasahara S, Clark EA, Ledbetter JA (2011) Anti-CD180 (RP105) activates B cells to rapidly produce polyclonal Ig via a T cell and MyD88-independent pathway. J Immunol 187(8):4199–4209CrossRef
4.
go back to reference Chaplin JW, Chappell CP, Clark EA (2013) Targeting antigens to CD180 rapidly induces antigen-specific IgG, affinity maturation, and immunological memory. J Exp Med 210(10):2135–2146CrossRef Chaplin JW, Chappell CP, Clark EA (2013) Targeting antigens to CD180 rapidly induces antigen-specific IgG, affinity maturation, and immunological memory. J Exp Med 210(10):2135–2146CrossRef
5.
go back to reference Miguet L, Lennon S, Baseggio L, Traverse-Glehen A, Berger F, Perrusson N, Chenard MP, Galoisy AC, Eischen A, Mayeur-Rousse C, Maar A, Fornecker L, Herbrecht R, Felman P, van Dorsselaer A, Carapito C, Cianférani S, Mauvieux L (2013) Cell-surface expression of the TLR homolog CD180 in circulating cells from splenic and nodal marginal zone lymphomas. Leukemia 27(8):1748–1750CrossRef Miguet L, Lennon S, Baseggio L, Traverse-Glehen A, Berger F, Perrusson N, Chenard MP, Galoisy AC, Eischen A, Mayeur-Rousse C, Maar A, Fornecker L, Herbrecht R, Felman P, van Dorsselaer A, Carapito C, Cianférani S, Mauvieux L (2013) Cell-surface expression of the TLR homolog CD180 in circulating cells from splenic and nodal marginal zone lymphomas. Leukemia 27(8):1748–1750CrossRef
6.
go back to reference Mayeur-Rousse C, Guy J, Miguet L, Bouyer S, Geneviève F, Robillard N, Solly F, Maar A, Bené MC, Mauvieux L, on behalf of the GEIL (Groupe d'Etude Immunologique des Leucémies) and GEIL (Groupe d'Etude Immunologique des Leucémies) (2016) CD 180 expression in B-cell lymphomas: a multicenter GEIL study. Cytometry B Clin Cytom 90(5):462–466CrossRef Mayeur-Rousse C, Guy J, Miguet L, Bouyer S, Geneviève F, Robillard N, Solly F, Maar A, Bené MC, Mauvieux L, on behalf of the GEIL (Groupe d'Etude Immunologique des Leucémies) and GEIL (Groupe d'Etude Immunologique des Leucémies) (2016) CD 180 expression in B-cell lymphomas: a multicenter GEIL study. Cytometry B Clin Cytom 90(5):462–466CrossRef
7.
go back to reference Wu J, Sheng Y, Sui JN, Weng XQ (2018) Characteristics of CD180 expression and its diagnostic value in B cell chronic lymphoproliferative disorders. Zhongguo shi yan xue ye xue za zhi 26(6):1811–1815PubMed Wu J, Sheng Y, Sui JN, Weng XQ (2018) Characteristics of CD180 expression and its diagnostic value in B cell chronic lymphoproliferative disorders. Zhongguo shi yan xue ye xue za zhi 26(6):1811–1815PubMed
8.
go back to reference Mestrallet F, Sujobert P, Sarkozy C, Traverse-Glehen A, Callet-Bauchu E (2016) CD180 overexpression in follicular lymphoma is restricted to the lymph node compartment. Cytometry B Clin Cytom 90(5):433–439CrossRef Mestrallet F, Sujobert P, Sarkozy C, Traverse-Glehen A, Callet-Bauchu E (2016) CD180 overexpression in follicular lymphoma is restricted to the lymph node compartment. Cytometry B Clin Cytom 90(5):433–439CrossRef
9.
go back to reference Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA et al (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. International Agency for Research on Cancer (IARC), Lyon, pp 407–410 Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA et al (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. International Agency for Research on Cancer (IARC), Lyon, pp 407–410
10.
go back to reference Ikeda JI, Kohara M, Tsuruta Y, Nojima S, Tahara S, Ohshima K, Kurashige M, Wada N, Morii E (2017) Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma. Hum Pathol 59:70–79CrossRef Ikeda JI, Kohara M, Tsuruta Y, Nojima S, Tahara S, Ohshima K, Kurashige M, Wada N, Morii E (2017) Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma. Hum Pathol 59:70–79CrossRef
11.
go back to reference Lachar WA, Shahab I, Saad AJ (2007) Accuracy and cost-effectiveness of core needle biopsy in the evaluation of suspected lymphoma: a study of 101 cases. Arch Pathol Lab Med 131(7):1033–1039PubMed Lachar WA, Shahab I, Saad AJ (2007) Accuracy and cost-effectiveness of core needle biopsy in the evaluation of suspected lymphoma: a study of 101 cases. Arch Pathol Lab Med 131(7):1033–1039PubMed
12.
go back to reference Hu Q, Naushad H, Xie Q, Al-Howaidi I, Wang M, Fu K (2013) Needle-core biopsy in the pathologic diagnosis of malignant lymphoma showing high reproducibility among pathologists. Am J Clin Pathol 140(2):238–247CrossRef Hu Q, Naushad H, Xie Q, Al-Howaidi I, Wang M, Fu K (2013) Needle-core biopsy in the pathologic diagnosis of malignant lymphoma showing high reproducibility among pathologists. Am J Clin Pathol 140(2):238–247CrossRef
13.
go back to reference Wang Z, Cook JR (2019) IRTA1 and MNDA expression in marginal zone lymphoma: utility in differential diagnosis and implications for classification. Am J Clin Pathol 151(3):337–343CrossRef Wang Z, Cook JR (2019) IRTA1 and MNDA expression in marginal zone lymphoma: utility in differential diagnosis and implications for classification. Am J Clin Pathol 151(3):337–343CrossRef
14.
go back to reference Yoon SI, Hong M, Wilson IA (2011) An unusual dimeric structure and assembly for TLR4 regulator RP105–MD-1. Nat Struct Mol Biol 18(9):1028–1035CrossRef Yoon SI, Hong M, Wilson IA (2011) An unusual dimeric structure and assembly for TLR4 regulator RP105–MD-1. Nat Struct Mol Biol 18(9):1028–1035CrossRef
15.
go back to reference Yeh TC, O'Connor G, Petteruti P, Dulak A, Hattersley M, Barrett JC, Chen H (2017) Identification of CCR2 and CD180 as robust pharmacodynamic tumor and blood biomarkers for clinical use with BRD4/BET inhibitors. Clin Cancer Res 23(4):1025–1035CrossRef Yeh TC, O'Connor G, Petteruti P, Dulak A, Hattersley M, Barrett JC, Chen H (2017) Identification of CCR2 and CD180 as robust pharmacodynamic tumor and blood biomarkers for clinical use with BRD4/BET inhibitors. Clin Cancer Res 23(4):1025–1035CrossRef
Metadata
Title
Expression of CD180 in common B cell neoplasms using immunohistochemistry
Authors
Ahmad T. Mansour
Tamadur A. Mahasneh
Sahar Mustafa
Sarah Shawash
Omar Jaber
Tariq N. Adily
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
Journal of Hematopathology / Issue 4/2020
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI
https://doi.org/10.1007/s12308-020-00420-w

Other articles of this Issue 4/2020

Journal of Hematopathology 4/2020 Go to the issue